On February 19, 2026, the U.S. telehealth giant Hims & Hers Health, Inc. entered into an agreement to acquire Eucalyptus, Australia's leading digital health platform. The transaction is valued at up to $1.15B (USD). This agreement marks one of the largest cross-border M&A deals in the telehealth sector, signaling a shift from domestic competition to domination in the global platform. 

Eucalyptus provides Hims & Hers with an immediate turnkey entry into Australia and Japan while significantly strengthening its existing operations in the UK, Germany, and Canada. For instance, Eucalyptus’s brand, Juniper, is a global leader in medical weight management. By acquiring Eucalyptus, Hims & Hers secures a proven infrastructure for distributing GLP-1 medications (i.e., semaglutide) internationally, which taps into the multi-billion dollar anti-obesity market. Both companies share a direct-to-consumer (DTC) model, focusing on destigmatizing healthcare, including men’s health, women’s health, and dermatology. 

This strategy aligns with the rapid rise in GLP-1 drugs, which are increasingly delivered toward digitally managed, subscription-based care models. Control over GLP-1’s distribution, a market projected to generate $10B in revenue by 2030, represents a strategically valuable position for any telehealth company. Consolidation among telehealth companies would strengthen market share and, importantly, centralize control of patient acquisition through brand recognition and direct-to-consumer channels. These platforms are capable of producing high-volume patient inflows, which—when combined with recurring subscriptions, long treatment durations, and potential cross-sell expansion of post-treatment care—significantly increase patient lifetime value while keeping acquisition costs fixed. 

The $1.15B price tag is not paid all at once. It consists of $240M upfront in cash, $710M in deferred payments over 18 months, and $200M in performance-based earn-out tied to revenue and EBITDA targets through 2029. This payment protects Hims & Hers if Eucalyptus fails to maintain its triple-digit growth. Further, it ensures the Eucalyptus founders (including CEO Tim Doyle, who will become SVP of International) remain motivated to hit aggressive targets post-acquisition. By using deferred payments and stock options (up to 60%), Hims & Hers preserves its cash flow for ongoing U.S. operations.

This deal suggests that the telehealth industry is entering a consolidation phase where a few global giants will replace hundreds of local startups. The merger emphasizes a shift toward a personalized and proactive form of healthcare. We can expect more mega-mergers between AI-driven diagnostic companies and pharmacy-distribution platforms. If this ‘cross-border’ deal clears regulatory hurdles in Australia and the U.S., it will set the blueprint for how digital health companies in the U.S. will navigate different national healthcare laws.

For a comprehensive evaluation of the merger, one can consider the deal in three possible scenarios. In the base case, Hims & Hers grows to become a legitimate distributor of phamaceutical medications. While margins on compounded drugs may shrink due to regulation, the $200M performance-based earn-out ensures Eucalyptus remains incentivized to pivot toward branded oral GLP-1s. Here, the deal secures Hims & Hers' position as one of the Big Three global telehealth giants providing cross-border digital health. In the bear case, Hims & Hers confront the risk of a financial bubble driven by GLP-1 drug shortages. As of March 2026, the FDA and TGA have significantly increased oversight of non-branded medications. Much of the company’s current success stems from brand-name drugs (i.e., Wegovy) being under short supply, which legally enables them to sell cheaper, non-branded versions. However, if the FDA (or likewise, the Australian TGA) decides the shortage is over, there will no longer be a legal 'loophole.' Further, Big Pharma giants such as Eli Lilly and Novo Nordisk are currently suing over safety concerns. Consequently, this could lead to massive fines or a total ban on their best-selling products, making the $1.15B price tag seem more like an overpayment. In the bull case, the acquisition enables Hims & Hers to establish its position as a global powerhouse of digital healthcare. The company integrates Eucalyptus’s ACHS-accredited infrastructure to dominate the international market, as it expands its outreach into Australia and Japan. This enables a massive expansion of Patient Lifetime Value (LTV). Once a patient enters the ecosystem through a high-intent product like Juniper’s GLP-1 program, the platform can cross-sell dermatology, mental health, and hair loss treatments on a global scale. As such, this turns healthcare into a digital subscription model, where a company is not merely relying on one trendy drug for its profit but on a diversified source of revenue.

In essence, this acquisition is a major step toward Hims & Hers becoming a global consumer health platform. It is a mobile-first, software-driven, and globally integrated model where high-quality healthcare proves as accessible as any other digital subscription. The success of this deal proves that the future of healthcare is no longer confined to physical medical clinics and conventional telehealth services.